Association of galectins-1 and -3 with proangiogenic factors and endothelial dysfunction in colon cancer

Abstract

BACKGROUND: A key role in the pathogenesis of colon cancer is assigned to inducers of neoangiogenesis — vascular endothelial and epidermal growth factors, the effects of which can probably be modulated by galectins-1 and -3.

AIM: To study the relationship between the content of galectins-1 and -3, vascular endothelial and epidermal growth factors with the number of circulating endothelial cells in the blood of patients with colon cancer, depending on the degree of tumor differentiation and its spread.

MATERIAL AND METHODS: Patients (n=20) with a verified diagnosis of colon cancer (International Classification of Diseases code C18–C20) were examined; the comparison group included healthy volunteers (n=10), matched by gender and age. The study material was peripheral blood. The content of galectin-1, galectin-3, vascular endothelial and epidermal growth factors was assessed by enzyme immunoassay, and counting of desquamated endothelial cells was assessed by flow cytometry. Statistical processing was performed in the Jamovi 2.3.21 software package for Windows. Differences between samples were assessed by calculating the Mann–Whitney U test. Relationships were established by calculating the Spearman correlation coefficient (ρ). The results were considered reliable at the level of statistical significance p <0.05.

RESULTS: In patients with colorectal cancer, the level of vascular endothelial factor was higher than in healthy donors by 18%, the level of galectin-1 was 2.6 times higher, galectin-3 was 1.6 times higher compared to healthy donors, the level of epidermal growth factor did not differ significantly. The content of galectins-1 and -3 was closely interrelated (ρ=0.843, p <0.01), with the content of vascular endothelial growth factor in the blood plasma (ρ=0.311, p=0.032 — galectin-1; ρ=0.310, p <0.033 — galectin-3, respectively). The number of desquamated endothelial cells in the blood of patients with colorectal cancer was 8 times higher than in healthy people, and directly correlated with the content of vascular endothelial growth factor (ρ=0.307, p <0.05), galectin-1 (ρ=0.650, p <0.01) and galectin-3 (ρ=0.622, p <0.01).

CONCLUSION: An increase in the content of galectins-1 and -3 in the blood plasma of patients with colon cancer positively correlates with the expression of vascular endothelial growth factor, and does not depend on the stage of the disease and the degree of tumor differentiation.

Keywords

colon cancer / galectins / epidermal growth factor / vascular endothelial growth factor / desquamated endothelial cells

References

[1] Kaprin AD, Starinskii VV, Shakhzadova AO. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu. (The state of cancer care for the population of Russia in 2021.) Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMITS radiologii” Minzdrava Rossii; 2022. 239 р. (In Russ.)

[2] Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.

[3] Korchagina AA, Shein SA, Gurina OI, Chekhonin VP. VEGFRs in neoplastic angiogenesis and prospects for therapy cf brain tumors. Annals of the Russian Academy of Medical Sciences. 2013;68(11):104–114. (In Russ.) doi: 10.15690/vramn.v68i11.851

[4] Корчагина А.А., Шеин С.А., Гурина О.И., Чехонин В.П. Роль рецепторов VEGFR в неопластическом ангиогенезе и перспективы терапии опухолей мозга // Вестник Российской академии медицинских наук. 2013. Т. 68, № 11. С. 104–114. doi: 10.15690/vramn.v68i11.851

[5] Svetozarskiy NL, Artifeksova AA, Svetozarskiy SN. Growth promoting factor of endothelium of vessels: biological properties and practical value (literature review). Journal of Siberian Medical Sciences. 2015;(5):24. (In Russ.) EDN: VDVAKJ

[6] Светозарский Н.Л., Артифексова А.А., Светозарский С.Н. Фактор роста эндотелия сосудов: биологические свойства и практическое значение (обзор литературы) // Journal of Siberian Medical Sciences. 2015. № 5. С. 24. EDN: VDVAKJ

[7] Olzhaev ST, Toksanbayev DS, Tseimakh AE, Sadykov NK. Endothelial dysfunction in some malignant neoplasms of digestive system. Vysokotekhnologicheskaya meditsina. 2022;9(3):4–9. (In Russ.) doi: 10.52090/2542-1646_2022_9_3_4

[8] Олжаев С.Т., Токсанбаев Д.С., Цеймах А.Е., Садыков Н.К. Эндотелиальная дисфункция при некоторых злокачественных новообразованиях органов системы пищеварения // Высокотехнологическая медицина. 2022. Т. 9, № 3. С. 4–9. doi: 10.52090/2542-1646_2022_9_3_4

[9] Topuzova MP, Alekseeva TM, Vavilova TV, Sirotkina OV, Klocheva EG. Circulating endothelial cells and endothelial progenitor cells as a marker of endothelial dysfunction in hypertensive patients survived after ischemic stroke (review). Arterial hypertension. 2018;24(1):57–64. (In Russ.) doi: 10.18705/1607-419X-2018-24-1-57-64

[10] Топузова М.П., Алексеева Т.М., Вавилова Т.В., и др. Циркулирующие эндотелиоциты и их предшественники как маркёр дисфункции эндотелия у больных артериальной гипертензией, перенёсших ишемический инсульт (обзор) // Артериальная гипертензия. 2018. Т. 24, № 1. С. 57–64. doi: 10.18705/1607-419X-2018-24-1-57-64

[11] Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer. 2006;6(11):835–845. doi: 10.1038/nrc1971

[12] Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification // Nat Rev Cancer. 2006. Vol. 6, N. 11. P. 835–845. doi: 10.1038/nrc1971

[13] Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998;246(3):788–791. doi: 10.1006/bbrc.1998.8708

[14] Ochieng J., Leite-Browning M.L., Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3 // Biochem Biophys Res Commun. 1998. Vol. 246, N. 3. P. 788–791. doi: 10.1006/bbrc.1998.8708

[15] Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1–18. doi: 10.1146/annurev.med.57.121304.131306

[16] Folkman J. Angiogenesis // Annu Rev Med. 2006. Vol. 57. P. 1–18. doi: 10.1146/annurev.med.57.121304.131306

[17] Dignat-George F, Sampol J, Lip GY, Blann AD. Circulating endothelial cells: Realities and promises in vascular disorders. Pathophysiol Haemost Thromb. 2004;33(5–6):495–499.

[18] Dignat-George F., Sampol J., Lip G.Y., Blann A.D. Circulating endothelial cells: Realities and promises in vascular disorders // Pathophysiol Haemost Thromb. 2004. Vol. 33, N. 5–6. P. 495–499.

[19] Thijssen VV. Galectins in endothelial cell biology and angiogenesis: The basics. Biomolecules. 2021;11:1386. doi: 10.3390/bioml1091386

[20] Thijssen V.V. Galectins in endothelial cell biology and angiogenesis: The basics // Biomolecules. 2021. Vol. 11. P. 1386. doi: 10.3390/bioml1091386

[21] Tatsuyoshi F, Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24(10):886–891. doi: 10.1093/glycob/cwu086

[22] Tatsuyoshi F., Funasaka T., Raz A., Nangia-Makker P. Galectin-3 in angiogenesis and metastasis // Glycobiology. 2014. Vol. 24, N. 10. P. 886–891. doi: 10.1093/glycob/cwu086

[23] Kozich ZhM, Smirnova LA, Martinkov VN. Tumor progression and the role of galectins. Meditsinskie novosti. 2020;(11):3–7. (In Russ.)

[24] Козич Ж.М., Смирнова Л.А., Мартинков В.Н. Опухолевая прогрессия и роль галектинов // Медицинские новости. 2020. № 11. С. 3–7.

[25] Kolobovnikova YuV, Urazova OI, Poletika VS, Reyngardt GV, Romanova EV, Kurnosenko AV, Dmitrieva AI, Yankovich KI, Grishchenko MYu. Galectin-1 and Galectin-3 expression in colon cancer and its correlation with tumor invasion, differentiation, and metastatic spread. Fundamental and Clinical Medicine. 2021;6(4):45–53. (In Russ.) doi: 10.23946/2500-0764-2021-6-4-45-53

[26] Колобовникова Ю.В., Уразова О.И., Полетика В.С., и др. Особенности экспрессии галектинов 1 и 3 при раке толстого кишечника во взаимосвязи с клинико-морфологическими параметрами опухоли // Фундаментальная и клиническая медицина. 2021. Т. 6, № 4. С. 45–53. doi: 10.23946/2500-0764-2021-6-4-45-53

[27] Chizh GA. Modern possibilities for forecasting the metastasis of malignant non formations. Metastasing markers. FORCIPE. 2019;(1):31–41. (In Russ.) EDN: MHQIPE

[28] Чиж Г.А. Современные возможности прогнозирования метастазирования злокачественных новообразований. Маркёры метастазирования // FORCIPE. 2019. № 1. С. 31–41. EDN: MHQIPE

[29] Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M. Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci. 2018;19(9):2577. doi: 10.3390/ijms19092577

[30] Paschke S., Jafarov S., Staib L., et al. Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer // Int J Mol Sci. 2018. Vol. 19, N. 9. P. 2577. doi: 10.3390/ijms19092577

[31] Jafarov S, Link KH. Colon and rectal cancer are different tumor entities according to epidemiology, carcinogenesis, molecular- and tumor biology, primary and secondary prevention: preclinical evidence. Siberian journal of oncology. 2018;17(4):88–98 (In Russ.) doi: 10.21294/1814-4861-2018-17-4-88-98

[32] Jafarov S., Link K.H. Различие рака толстой и прямой кишки с точки зрения эпидемиологии, кацерогенеза, молекулярной биологии, первичной и вторичной профилактики: доклинические исследования // Сибирский онкологический журнал. 2018. Т. 17, № 4. С. 88–98. doi: 10.21294/1814-4861-2018-17-4-88-98

Funding

Исследование выполнено при финансовой поддержке Совета по грантам Президента Российской Федерации для государственной поддержки молодых российских учёныхhe study was carried out with financial support from the Grant Council of the President of the Russian Federation for state support of young Russian scientists(МД-2788.2019.7)

RIGHTS & PERMISSIONS

Eco-Vector